An initiative to exchange extended RBC phenotyping information using FHIR

John C. Spinosa, MD, PhD
Lantana Consulting Group
Need

• **Blood donor centers** have computer systems geared toward effective and safe manufacture of blood products—Blood establishment computer systems (BECs)

• **Health system blood banks** have computer systems geared toward effective and safe transfusion of manufactured blood products—Blood bank laboratory information systems (BBLIS)

• Both systems manage blood products and associated metadata for the units that are transferred between them.

• **Barcodes provide a minimal digital interface**—most of the metadata about the products are rekeyed
Importance

• Registering blood products manually was tolerable when the amount of metadata was relatively small

• Molecular techniques are rapidly changing this.
  • Automated instruments are increasing the speed and ease of having larger serologic characterization of blood products
  • Nucleic acid molecular techniques (arrays, mass spec, targeted sequencing, gene sequencing) expand and extend genotypic predictions of RBC phenotypes—5 features->30 features->350 features
  • Blood product compatibility is not localized: the search for compatible blood can be regional, national, and (rarely) international
  • Increasingly, donors will be characterized genotypically and donors eventually become patients—transferring genotyping is important
  • Sharing extended phenotyping information between patients and blood donors
    • Supports allocation of compatible blood products.
    • Prevents allo-antibody generation which benefits patients, especially those who require chronic transfusions
Proposal

• Lantana is working with partners to:
  • Develop a standard for exchange of blood product genotyping and phenotyping information for BECS and BBLIS incorporation
  • Expand and convene a group of key stakeholders to launch this work and support it with domain expertise
  • Leverage the momentum of the core group and standards development project to procure funding that will carry through feasibility (Connectathon) testing, ballot, ballot reconciliation, and publication

• Current efforts
  • Supporting parties to date—San Diego Blood Bank, HaploGNX
  • HL7 working group presentations this week—O&O, Public Health WG, Clinical Genomics WG (in 2-3 weeks)
  • Professional organizations contacted and evaluating
  • Some vendors contacted and evaluating

• Requesting feedback, information on related efforts, WG sponsorship, stakeholder participation
Contact

• If interested in discussing and participating, please contact:
  • John Spinosa john.spinosa@lantanagroup.com